GSE216757 decitabine fibroblast 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE216757_decitabine_fibroblast_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE216757_decitabine_fibroblast_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE216757_decitabine_fibroblast_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE216757_decitabine_fibroblast_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

H2B clustered histone 8

Gene

H19 imprinted maternally expressed transcript

Gene

H2A clustered histone 11

Gene

p53 upregulated regulator of p53 levels

Gene

MIR34A host gene

Gene

zinc finger protein 204, pseudogene

Gene

activator of HSP90 ATPase homolog 2, pseudogene

Gene

HLA complex group 11

Gene

embryonic stem cell related

Gene

long intergenic non-protein coding RNA 472

  • Gene

    H2B clustered histone 8


  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    H2A clustered histone 11


  • Gene

    p53 upregulated regulator of p53 levels



  • Gene

    zinc finger protein 204, pseudogene


  • Gene

    activator of HSP90 ATPase homolog 2, pseudogene


  • Gene

    HLA complex group 11


  • Gene

    embryonic stem cell related


  • Gene

    long intergenic non-protein coding RNA 472

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.